Oral weight loss pills work well in clinical trials and are positioned as an alternative to injections GLP-1 drug Like Ozempic and Wegovy.
According to a press release, Eli Lilly Drug, known as Orforglipron, demonstrated “meaningful weight loss” and improved cardiac metabolism.
The Phase 3 ATIAN-1 trial, published in the New England Journal of Medicine, evaluated the safety and efficacy of drugs in adults with weight-related medical problems. I don’t have diabetes.
Weight loss pills could add years to American lives, researchers project
Participants received 72 weeks of treatment at three different doses (6 mg, 12 mg, and 36 mg).
After the trial period, results showed that orfogripron met the “primary endpoint of superior weight loss” compared to placebo.
Those who took the highest dose lost an average of 27.3 pounds. Nearly 60% of these participants lost 10% of their body weight, and 39.6% lost at least 15%.
At the start of the study, up to 91% of the 1,127 prediabetic participants achieved nearly normal blood glucose levels compared to 42% taking placebo.
Orforglipron demonstrated “clinically meaningful improvements” in associated cardiovascular risk factors Being obesesuch as non-HDL cholesterol, systolic blood pressure, triglycerides.
Common weight loss medications can relieve painful arthritis symptoms, doctors report
The highest dose also reduced the marker of inflammation, called highly sensitive C-reactive protein, by 47.7%.
This study found that the safety profile of this drug is consistent with existing GLP-1 drugs. The most common side effects were mild to moderate severity, including nausea, constipation, diarrhea and vomiting.
Sean Wharton, Maryland, Director of Wharton Medical Clinic and Canadian lead research author, writing that obesity is a “complex, global health challenge” that requires treatment options “effective and easy to integrate into everyday life.”
“Next Ozempic” aims to provide 30% weight loss with fewer side effects
“In this phase 3 study, Orforglipron showed strong efficacy outcomes and safety consistent with the GLP-1 class, strengthening its potential as a primary care first-line treatment,” he said in a press release.
“Orforglipron helps reduce known markers of cardiovascular risk associated with obesity and support meaningful improvements. Public Health. ”
Lily announced that she is moving forward with plans to get approval for Orforglipron as an obesity drug. The company expects to get the green light in 2026. In the same year, he plans to apply for approval to use the medication for the treatment of type 2 diabetes.
Reuters reported that the pill could be “quickly tracked” under a one-to-two month review process launched by the Food and Drug Administration, according to a Wall Street analyst.
“Analysts speculate that Orforglipron, a drug, is a viable candidate given the increased cost burden of expensive injectable weight loss drugs and the fact that Lily is expanding US manufacturing.
Click here to sign up for our health newsletter
In an interview with Fox News Digital, New York City’s medical weight loss doctor Sue Decotiis, MD and Sue Decotiis called the drug a “positive addition to armor” that is cheaper to produce and cheaper for consumers.
However, Decotiis states that the results of injections such as Ozempic and Mounjaro are “not impressive” in weight loss results.
“But orforglipron’s compliance may be better. Oral medication It’s not injectable,” she said.
According to Decotiis, one concern about the new drug is that it is “easy for the body to metabolize and regulate it,” rather than a peptide with a high safety factor.
For health articles, please visit www.foxnews.com/health
“The long-term outcomes we didn’t know yet may be unknown,” she added. “We hope that there are more oral weight loss medications in the pipeline and are in the peptide category.”
Fox News Digital reached out to Eli Lilly for comment.
